Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that they will work together to develop clinical applications of ...

Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to ...

A third "just in case" service to proactively store induced pluripotent stem (iPS) cells created with a client's blood for ...

A Kyoto-based regenerative medicine company is launching a service that will allow individuals to generate and store induced ...

A Kyoto-based regenerative medicine company is launching a service that will allow individuals to generate and store induced ...

History is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up with Panasonic and Japan’s Kyoto University, where the first mouse iPS ...

Induced pluripotent stem cells (iPS cells) can be created from any tissue in the human body and possess the ability to transform into a wide range of tissues. Kobe University MARUYAMA Tatsuo and his ...

PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells ...

A joint research team led by Dr. Akira Kunitomi, a former postdoctoral fellow at CiRA (currently a researcher at the Gladstone Institute of Cardiovascular Disease), and ID Pharma Co., Ltd., has ...

Japan has cleared two therapies that began with the same lab technique and ended in very different parts of the body. One is ...